Kolexia
Marijon Helene Oncologie médicale
Marijon Helene
Oncologie médicale
Hôpital Franco-Britannique
Levallois-Perret, France
55 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du sein Tumeurs du sein triple-négatives Carcinomes Tumeurs du foie Carcinome hépatocellulaire Carcinome épithélial de l'ovaire Tumeurs de l'ovaire {{person.topmesh10.name}}

Collaborateurs

Voir plus
Iurisci Ida
Iurisci Ida
Gcs 3c Inst Oncologie Hds Nord Siege, Levallois-Perret, France
Perez-Staub Nathalie
Perez-Staub Nathalie
Hôpital Franco-Britannique, Levallois-Perret, France
Gervais Honorine
Gervais Honorine
Hôpital Franco-Britannique, Levallois-Perret, France
Rouchou-Bloch Delphine
Rouchou-Bloch Delphine
Hôpital Franco-Britannique, Levallois-Perret, France

Industries

Voir plus
Ipsen
13 collaboration(s)
Dernière en 2023
AstraZeneca
10 collaboration(s)
Dernière en 2023
MSD
10 collaboration(s)
Dernière en 2023
Janssen
7 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Abstracts: AACR Special Conference in Cancer Research: Advances in Breast Cancer Research   01 décembre 2023
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Oncotarget   31 août 2021
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.
World journal of clinical oncology   01 octobre 2020
FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer.
2018 Gastrointestinal Cancers Symposium   26 février 2018
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie   20 février 2018
Her2 a paradigm for targeted therapy.
Bulletin du cancer   04 novembre 2011
Survival according to residual disease after interval laparotomy in advanced epithelial ovarian cancer.
2011 ASCO Annual Meeting I   20 mai 2011
Could baseline health-related quality of life (QoL) improve prognostication of overall survival in metastatic colorectal cancer? Results from GERCOR OPTIMOX 1 study.
2011 ASCO Annual Meeting I   20 mai 2011
Center impact on survival in metastatic colorectal cancer trials.
2011 ASCO Annual Meeting I   20 mai 2011
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma.
Journal of hepatology   02 décembre 2010